InvestorsHub Logo
Followers 0
Posts 13277
Boards Moderated 0
Alias Born 05/06/2016

Re: topdog52 post# 112575

Tuesday, 09/06/2016 2:40:52 PM

Tuesday, September 06, 2016 2:40:52 PM

Post# of 121642
Easy answer: Since the company's out of business, NO.

Can MDIN still sell the Lactose Intolerance Formula when it comes out in a couple of months?


Why not ask Gay Farton or the lying CEO WTF is happening? But you'll never get an honest answer out of either one!

If they haven't succeeded in getting their main product into a single retailer in 4 years, there's NO CHANCE of them releasing a lactose product. They may have sold the license to someone else long ago and never said anything. That's the sort of thing that can be expected from a company which has defrauded its shareholders every chance they got! And whose owner has done the same in other stocks he owned.


As I posted in the MNZO board, I sent Ken some messages about MDIN's patent license and received two replies.


Subject: Lacto-Freedom partner?

Message:
I see that LF is due to be released this year.
Will MedGen be involved in any way? It was announced 3 years ago that Northstar Global had acquired a patent license, so will they be marketing LF, or do they simply have the right to market their own competing product?
Since MedGen has done nothing but release lies for 3 years, that story is probably 100% bogus too.

Reply 1:

Subject: RE: Manzo Pharmaceuticals, Inc. Contact: Lacto-Freedom partner?
From: "Ken ." <manzopharma@outlook.com>
Date: Wed, May 4, 2016 8:33 am

Yes, I expect it to be released this August. Northstar's exploratory agreement has expired and I have not heard from them to renew it or license the probiotic since the human study.



I sent a follow-up message:

Subject: RE: Manzo Pharmaceuticals, Inc. Contact: Lacto-Freedom partner?

Thanks for the info but that's not consistent with what Jason Sindleman, the previous CEO reported in a sworn financial report: "400,000,000 Common shares issued Celprogen Inc. located in San Pedro California. The asset is an unlimited license to use their patent for a lactose intolerance cure and the only term is that the company pay a 2% royalty on the net profit generated annually."

How could the license have expired if it was unlimited and expected to result in producing revenue and royalties year after year?


Reply 2:

Subject: RE: Manzo Pharmaceuticals, Inc. Contact: Lacto-Freedom partner?
From: "Ken ." <manzopharma@outlook.com>
Date: Wed, July 13, 2016

I have no affiliation with Northstar so I can not confirm 400M shares paid to Celprogen.... You are correct about the license agreement not expiring. I recently reviewed it. The ORIGINAL draft was a period of 2 years. Celprogen's attorney updated it several times and I did not read the final draft. I am disappointed that nothing has happened with the probiotic and Northstar, but maybe now with human studies they will be interested again. Nicholas Chieco was the CEO I dealt with in the past and he is no longer there from what I understand.